CRISPR dispute raises bigger patent issues that we're not talking about Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, April 09, 2016

CRISPR dispute raises bigger patent issues that we're not talking about



Opinion

 Consider a similar situation, the now-famous case of biotechnology company Myriad Genetics’ patents on the BRCA genes, which confer increased susceptibility for breast and ovarian cancer.
 And in the future, we should seriously consider the importance of the patent system – almost by default – in shaping the moral dimensions of science and technology.

0 comments :

Post a Comment

Your comments?